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1. ABSTRACT 
 
Chlamydia trachomatis (C. trachomatis) is a leading cause of bacterial sexually 
transmitted infections in developed and undeveloped countries, and therefore a global public 
health issue. In an era of increasing bacterial resistance to antibiotics, resistance has been an 
exceedingly rare phenomenon in C. trachomatis; however, clinical treatment failures 
attributed to multidrug-resistant C. trachomatis strains have been described on several 
occasions. Cell culture systems using McCoy cells and subsequent immunofluorescent 
staining are still the most common methodology used for antimicrobial susceptibility testing, 
but the presence of resistance markers should be appraised by further genetic analysis. 
Azithromycin resistance of C. trachomatis is often a result of the mutations in the peptidyl 
transferase region of 23S rRNA genes, tetracycline resistance is usually linked to the presence 
of foreign genomic islands integrated in chlamydial chromosome, whereas a predominant 
mechanism of fluoroquinolone resistance is a point mutation in the gyrA quinolone-
resistance-determining region. A nucleotide substitution in rpoB gene is responsible for 
rifampin resistance, and different mechanisms have been involved in the development of 
resistance to aminoglycosides, lincomycin and sulphonamide/trimethoprim combinations. 
 
 
2. INTRODUCTION 
 
Chlamydia trachomatis (C. trachomatis) is an obligate intracellular bacterium 
responsible for a variety of clinical syndromes that stem from genital and ocular mucous 
membranes infection, primarily transmitted due to unprotected sexually intercourse. 
Moreover, it is a leading cause of bacterial sexually transmitted infections (STIs) in both 
developed and undeveloped countries. In 2015 in the United States of America (USA), and in 
2014 in Europe, a total of 1 526 658 and 396 128 chlamydial infections were reported, 
respectively, giving an overall rate of 479 cases per 100,000 inhabitants in USA, and 187 
cases per 100,000 inhabitants in Europe (1,2). It should be noted that reported rates of 
chlamydia infection between European countries vary considerably (i.e. 549/100,000 in 
Denmark vs. 0.1/100,000 in Romania), which reflects the differences in chlamydia testing and 
case finding rather than real differences in chlamydia prevalence (2). 
 
C. trachomatis genome is the circular chromosome of a 1,042,519 base pairs (bp) 
which encodes minimal sets of genes needed for DNA replication, transcription and 
translation, and almost 900 protein-coding genes – including genes for peptidoglycan 
biosynthesis (3). Additionally, C. trachomatis carries a 7.5 kilobase (kb) plasmid that encodes 
eight plasmid glycoproteins which are not critical for chlamydial growth in vitro, but play a 
pivotal role in chlamydial pathogenesis (4). It has been shown that recombination as a way for 
altering the standard set of genes is not an unusual event in C. trachomatis. Recombination 
was first revealed within ompA gene which encodes the major outer membrane protein, 
following the identification of hotspots located near genes that code for virulence factors (5,6). 
Recently, C. trachomatis recombination was generated in vitro under antibiotic selection (7). 
 
C. trachomatis is characterized by its unique life cycle (Figure 1). The life cycle 
begins with infection of the host cell by elementary body (ET) – the infectious form 
characterized by spore-like cell-wall which enables C. trachomatis to survive outside of the 
host cell, and the ability to catabolize glucose, therefore providing the energy required for 
host cell entry and differentiation into the reticulate body (RB) (8). Upon attachment to the 
host cell, which is mediated by several bacterial ligands and receptors, the type III secretion 
system (T3SS) is injected, and ET is internalized into the inclusion (9). Transformation into 
RB follows, which is highly metabolically active and divides by binary fission within an 
inclusion that consequently grows until the entire cytoplasm is filled and the nucleus 
dislocated (Figure 1). A unique family of T3SS effectors termed inclusion membrane proteins 
are produced during establishment and maintenance of the inclusion providing its structural 
stability and acquisition of nutrients (9,10). After 24 to 74 hours of infection the transition of 
RB in ET in an asynchronous manner ensues, and finally, ET are released by host cell lysis 
and/or the extrusion of the inclusion (Figure 1). 
 
Another crucial characteristic of C. trachomatis is its capacity to establish the 
persistence. This is a reversible state that occurs in unfavourable growing or stress conditions 
in which C. trachomatis remains viable but shows atypical morphology and quiescent 
metabolism (11). In fact, the RTs upon stress (i.e. depletion of nutrients such as tryptophan 
and iron, and treatment with gamma-interferon and penicillin) are transformed into the 
enlarged aberrant bodies, and in such form they may successfully survive until the stress 
factor is removed. Stress response in persistence is associated with lack of RT to ET 
transformation (12) and the lack of septum synthesis (11). 
 
C. trachomatis causes the infection of lower and upper genital tract of both sexes, thus 
having the great influence on human reproductive health (13). The most common clinical 
manifestation is mucopurulent cervicitis in woman, and non-gonocccal urethritis in man. 
Untreated infection can ascend and lead to the severe complications such as pelvic 
inflammatory disease, ectopic pregnancy, chronic prostatitis and infertility in both sexes (14-
16).  The fact that complicates the diagnosis and subsequent treatment is that the most 
infections are asymptomatic (up to 70% in woman and 50% in man) (17,18). Such substantial 
rate of asymptomatic infections makes the screening programs – especially for high risk 
groups of population – crucial in timely diagnosis and treatment in order to prevent possible 
long-term consequences (19,20). 
 
Fortunately, chlamydial infection belongs to the curable STIs. Moreover, effective 
single-dose regimen of treatment with azithromycin exists (21). But regardless of a simple 
treatment regimen, STIs caused by C. trachomatis are continuously on the rise (1,2), which is 
manly attributed to the more frequent testing with improved detection systems such as nucleic 
acid amplification tests (NAATs) (22), but also changes in sexual behaviour and lack of 
education and prevention. Additionally, resistance to antibiotics of some STIs, particularly 
gonorrhoea and Mycoplasma genitalium infection, has increased rapidly in recent years, and 
reduced available treatment options for these infections (23,24). Such undesirable course of 
events with a possible increase of STIs prevalence (25) has raised concerns on antimicrobial 
resistance of all curable STIs. Although it seems to be very rare, C. trachomatis resistance 
exists, and may potentially also contribute to the increase of chlamydial infection. The aim of 
this review is to provide insight into the likelihood for appearance of C. trachomatis 
antimicrobial resistance, considering the frequency of its occurrence to date and molecular 
mechanisms of its development. 
 
 
3. TYPES AND FREQUENCY OF ANTIMICROBIAL RESISTANCE IN HUMAN 
ISOLATES OF C. TRACHOMATIS 
 
C. trachomatis is susceptible and treated with antibiotics that inhibit protein synthesis 
(tetracyclines and macrolides), and those that inhibit nucleic acid synthesis (fluoroquinolones 
and rifampin). Although it has been demonstrated that chlamydial persistence can be induced 
in vitro and in vivo when exposed to beta-lactam antibiotics (26,27), amoxicillin is still 
recommended as a third option in the treatment of pregnant women (28). 
 
Clinical treatment failures rates range from 5 to 23%, depends from the population 
tested (29). Although, majority of cases can be explained by post-treatment reinfection or lack 
of treatment compliance, some of them suggest true therapeutic failure caused by other 
reasons – including chlamydial resistance (30). Clinical treatment failures linked to the 
laboratory proved chlamydial resistance are not a common event in humans. A majority of 
studies report excellent susceptibility of chlamydial clinical isolates in laboratory and clinical 
settings (31-33). Quite opposite, in animals (particularly in swine), Chlamydia suis (C. suis) 
resistance as the result of selective pressure of continuous exposure to the tetracycline drugs 
which are used as additives is common (34,35). Selection for C. trachomatis antimicrobial 
resistance has been demonstrated in laboratory settings using serial passage of C. trachomatis 
strains in subinhibitory concentrations of rifampin, fluoroquinolones, and macrolides (36-38). 
There are few reports, but of considerable importance, that describe chlamydial antimicrobial 
resistance in vivo (39-43). All these reports informed about limited number of clinically 
detected and laboratory confirmed cases of C. trachomatis reduced susceptibility or 
antimicrobial resistance (Table 1). 
 
Basically, there are two types (or patterns) of described resistance in Chlamydia spp.: 
homotypic in which most of the organisms survive at concentrations well above the minimal 
inhibitory concentration (MIC), and heterotypic, a pattern in which small numbers of 
organisms (less than 1%) survive antimicrobial concentrations above MIC (44). All human 
resistant isolates showed heterotypic pattern of resistance (39-41), which has been also 
previously described in Staphylococcus spp. (45). In addition, chlamydial resistant isolates 
showed reduced viability (i.e. they could not survive long-term passage) or they lost their 
resistance upon passage. It is possible that heterotypic antibiotics resistance in chlamydia can 
be associated with aberrancy as is shown in the penicillin persistence model of Chlamydiae 
(46). Since homotypic antibiotic resistance has not yet been documented in C. trachomatis, 
Borel et al. hypothesise that some of the clinical treatment failure may be explained by 
development of heterotypic antibiotic resistance due to slower growth in certain environments 
or entry into a stress response in which the organisms are refractory to antibiotic treatment 
(47). 
 
One explanation of C. trachomatis resistance as a rare phenomenon in vivo despite 
selective pressure could be its unique developmental cycle. The impermeability of ET and 
isolation of RT (which readily exchanges DNA) within intracellular inclusion limit genetic 
exchange with non-self DNA (9), making it difficult for chlamydia to acquire the foreign 
antibiotic resistance gene (48). The other, more plausible explanation (which has shown to 
play important role in macrolide resistance) is that mechanisms which confer high-level 
resistance in chlamydiae severely affected chlamydial infectivity and may thus limit the 
emergence of highly resistant clones of these important pathogens in vivo (38). 
 
 
4. MAIN METHODS OF APPRAISING ANTIMICROBIAL RESISTANCE OF 
CHLAMYDIAL STRAINS 
 
Determining antimicrobial sensitivity of chlamydial strains is quite different from 
standard procedures in bacteriology, since it is necessary to demonstrate the ability (or 
inability) of C. trachomatis to multiply inside the cell in the presence of different 
concentrations of antibiotics (49). The resistant strains can be subsequently analysed with 
molecular techniques to ascertain potential genetic markers of resistance. Therefore systems 
based on cell culture with the addition of serially diluted concentrations of antibiotic represent 
traditional, but still the most commonly employed method of C. trachomatis sensitivity 
testing (44,50). However, there is still no universal testing methodology and the techniques 
that are used are time-consuming and technically challenging, which is the reason they are 
pursued only in highly specialized laboratories (46,49). 
 
A plethora of cell culture types of both human and animal origin can be used for 
testing, although McCoy cells derived from mouse fibroblasts provide the most reliable and 
consistent results (49,51). HeLa (human cervical adenocarcinoma), HL (human epithelial cells) 
and HEp-2 (human epidermoid laryngeal carcinoma) cell cultures can also be used, whereas 
Vero cells and primate kidney cell line BGMK are employed less frequently (44,49,51). In the 
past, the detection of intracellular inclusions after appropriate incubation period in such cell 
culture methods was done with iodine or Giemsa (52,53), but today uniform fluorescein-
labelled monoclonal antibodies are the best choice for visualization purposes (54). 
 
Regardless of a chosen cell line, a wide range of factors can influence the 
antimicrobial susceptibility testing results, most notably laboratory conditions such as pH, 
temperature, the polarity of the infected cells, the secretion of cytokines and the general 
nutritional content of the medium (51,55). Accordingly, it has been shown that a medium 
containing a high concentration of glucose, neutral pH and a high temperature during 
centrifugation (i.e. 33-35 °C) may yield a higher number of C. trachomatis inclusions (56), 
while polarized host cells enable more efficient transport and intracellular accumulation of 
antimicrobial drugs (57). Also, some additional factors that play include the size of the 
inoculum (it should not be less than 5000 inclusion forming units per well of microtiter plate), 
the period between the infection and the application of an antimicrobial drug, timely removal 
of the antibiotic, as well as the presence (or absence) of cycloheximide that is used to slow 
growth of the host cells (46,51). 
 
Still, the most important aspect for achieving reproducibility of results is to introduce 
standardized definitions of minimal inhibitory concentration (MIC) and minimal 
chlamydicidal concentration (MCC). To achieve this, it is highly recommended to introduce 
(and use) the transition point MIC (MICTP), defined as the concentration of drug where 90% 
or more of the inclusions have altered morphology and/or size (44). The MIC can then be 
defined as the concentration of drug that is one twofold dilution more concentrated that the 
MICTP, while the MCC is defined as the lowest concentration of drug at which no visible 
inclusions are observed after one passage from the cell culture that contains certain 
antimicrobial drug to the cell culture without them (44,58,59). 
 
An alternative approach is antimicrobial susceptibility testing of C. trachomatis strains 
by reverse transcription polymerase chain reaction (RT-PCR) based on the detection of 
specific DnaK transcript (60). The method also requires cell culture growth, followed by a 
molecular detection of live bacteria in the supernatant, with the advantage of detecting 
chlamydia in cultures deemed negative after immunofluorescent staining. In this approach, 
the MIC can be defined as the lowest concentration of antibiotic that inhibits the occurrence 
of a 318-bp product in the form of bands on the gel stained with ethidium bromide. 
 
The main advantage of the RT-PCR technique are corresponding (but consistently 
higher) MIC values when compared with cell culture method followed by immunofluorescent 
staining, as showed by Cross and his colleagues on the example of erythromycin and 
amoxicillin, which points to the improved sensitivity of this method (61). This can be 
explained by the adequately suppressed chlamydial growth in concentrations exceeding the 
MIC values measured in cell culture, but with a presence of low-level replication and the 
detection of RNA produced only by viable organisms (62). However, due to the questionable 
laboratory or clinical value of such aberrant inclusions with potential residual replication, a 
traditional cell culture system with a defined MICTP still represents a standard approach for 
antimicrobial susceptibility testing of C. trachomatis strains. 
 
One other method of appraising chlamydial antimicrobial sensitivity to standard 
antibiotics that did not gain much prominence is using flow cytometry after culturing C. 
trachomatis in McCoy cells and staining them with fluorescein isothiocyanate (FITC) 
antibodies, as described by Dessus-Babus et al. (63). After staining the infected cells show 
green fluorescence, which is reflected by the right-sided peak on the histograms. Nevertheless, 
it is necessary to evaluate two parameters before analysing the results – the percentage of 
positive cells and their mean fluorescence intensity (MFI) (63). The latter is a crucial 
parameter when assessing antibiotic activity, while the active concentration of the 
antimicrobial drug is expressed as inhibitory concentration 50 (IC50), which is the 
concentration necessary for a 50% reduction of the MFI when compared to the control 
without antibiotics. 
 
Although not as sensitive as classic immunofluorescent staining after incubation in 
cell culture, the main advantages of cultivation with detection by flow cytometry is its 
specificity, reproducibility and objective interpretation. The main disadvantage is the inability 
to detect “heterotypic resistance” due to insufficient sensitivity of detecting low levels of 
infection (51,63). In addition, the method is very cumbersome and time-consuming as flow 
cytometry necessitates a higher inoculum of chlamydia (more specifically 100,000 IFU/mL), 
not to mention a high price of equipment. Therefore this method today is rarely used, and it is 
hard to expect any further impact in the modern era of molecular techniques. 
 
 
5. RESISTANCE TO MACROLIDES – MUTATIONS IN CONSERVED REGIONS 
 
Macrolides are a class of broad-spectrum antimicrobials of large molecular size, and 
the group is saliently represented by a compound azithromycin (a part of azalide subclass with 
a 15-membered ring) as one of the drugs of choice for the treatment of C. trachomatis 
infection (64-66). The mechanism of action of the whole class is reversible binding to the 
large ribosomal subunit near the peptidyl-transferase center, stopping in turn the bacterial 
growth due to protein synthesis inhibition (64,65). Using a specifically-designed in vitro 
model, Binet and Maurelli described a population of C. trachomatis serovar L2 that was eight 
times less sensitive to azithromycin and four time less sensitive to erithromycin due to 
mutations of rplD gene which codes for ribosomal protein L4 (38). The substitution of neutral 
glutamine located at the position 66 with a positively charged lysine affects the binding of 
chlamydial ribosomal protein L4 to the corresponding 23S rRNA molecules. Even before the 
aforementioned experiment, it has been known that the mutations in the conserved regions of 
protein L4 affect the conformational change of the 23S rRNA in domains II, III and V (67,68), 
leading in turn to disruption of translational activity of ribosomes and, consequently,  
weakened action of the antibiotic in the peptidyl transferase center. 
 
Misyurina et al. described mutations A2058C i T2611C (according to E. coli 
numbering) in the peptidyl transferase region of 23S rRNA genes in clinical isolates resistant 
to erythromycin, azithromycin and josamycin (69). At the same time a triple mutation was 
found in a non-conserved region of the protein L22 (i.e. glutamine replacement with serine at 
position 52, arginine replacement with cysteine at position 65, as well as valine replacement 
with alanine at position 77) (69). The exact role of such amino acid replacements in the 
resistance of C. trachomatis is not yet fully elucidated, but it is assumed that they represent 
compensatory mutations to maintain virulence of the affected chlamydial strains. 
 
This is corroborated by the fact that the rplD gene mutations are linked to in vitro 
macrolide resistance of a myriad of clinically relevant microorganisms (70-72), they are often 
accompanied by additional mutations of 23S rRNA or rplV genes (encoding ribosomal protein 
L22) (73,74). Wolter and his colleagues showed that the survival of Streptococcus 
pneumoniae isolates resistant to macrolides due to mutations in ribosomal protein L4 is 
possible primarily because of secondary mutations that compensate for the defect in the 
bacterial growth (75). Since the resistant strains of C. trachomatis in the experimental model 
by Binet and Maurelli showed weaker growth, formed smaller inclusions and produced fewer 
infectious particles in the absence of the antibiotic (38), it seems that compensatory mutations 
are pivotal in the development of chlamydial resistance in vivo. 
 
 
6. RESISTANCE TO TETRACYCLINES – A PIVOTAL ROLE OF GENOMIC 
ISLANDS AND HORIZONTAL GENE TRANSFER 
 
Tetracyclines are a group of drugs that inhibit protein synthesis in bacteria by binding 
to their ribosome (with a high affinity to 30S subunit) and preventing the attachment of amino 
acyl-tRNA at the acceptor site (76). Doxycycline is a semisynthetic tetracycline that 
(alongside azithromycin) represents a first-line treatment against C. trachomatis (particularly 
for LGV strains) (65,77). However, although tetracycline usage is pervasive in human and 
veterinary medicine, their use has generally declined in recent decades due to the accounts of 
resistance in a wide array of different bacteria (47). Regarding C. trachomatis, mechanisms of 
resistance to tetracycline antibiotics have been described in detail in a closely related and 
highly recombinogenic species C. suis (34,46,78-80), and it was demonstrated that such 
resistance may be transferred to clinical isolates of C. trachomatis in vitro (81). 
 
Genetic characterization of resistant isolates revealed the presence of foreign genomic 
islands (between 6 and 13.5 kb) integrated in chlamydial chromosome (34). Each island 
harbors genes that encode antibiotic efflux pump (tet[C]) and regulatory repressor (tetR), a 
unique insertion sequence (IScs605), and up to ten additional genes involved in the replication 
and mobilization of the plasmid (34). Genomic islands of resistant C. suis that contain the 
gene tet[C] reveal 99% homology with the plasmid isolated from the Gram-negative 
bacterium Aeromonas salmonicida (A. salmonicida) found in fish (most notably trout and 
salmon) (34,82). Nevertheless, IScs605 insertion sequence was not detected in that plasmid, 
but in another aqueous Gram-negative bacterium – Laribacter hongkongensis – that is 
increasingly being recognized as a cause of gastroenteritis and traveler’s diarrhea in humans 
(83). A discovery of tet[C] represents the first description of the horizontal transfer of 
antibiotic resistance genes in any obligate intracellular bacterial species (46). 
 
Today, pig farming around the world still significantly relies on the prophylactic usage 
of tetracyclines, with fish being one of the commonly used sources of food (35,46). A large 
number of pigs in the United States is infected with resistant strains of C. suis (84-85), akin to 
the situation described in Belgium (86) and  Italy (87). It is believed that the plasmid enters 
the digestive system of pigs inside the bacterial species A. salmonicida characteristic for fish; 
on the other hand, as insertion sequences related to IScs605 are found in a plethora of 
bacterial species from the genus Helicobacter (88), as well as in already mentioned L. 
hongkongensis, the plasmid can acquire that sequence as well while passing through the 
gastrointestinal tract. The entire genomic island is then physically transferred to C. suis, 
anchoring next to TTCAA sequence within inv-like gene (34). 
 
The aforementioned process may be significant for C. trachomatis resistance 
development as well. In spite of the fact that the rise of resistance in this kind of natural 
ecosystem is very demanding, in laboratory conditions the transfer of resistance via 
homologous recombination between different strains can be achieved much faster and easier. 
Suchland and colleagues have shown that the transfer resistance markers from C. suis to C. 
trachomatis occurs almost routinely after co-cultivation of these two species (81). Therefore, 
a mere contact between the chlamydial strains resistant and sensitive to tetracyclines can 
enable the transfer of resistance genes and the development of resistant phenotype, which in 
patients treated with tetracyclines may result in the propagation and selection of such strains. 
 
Moreover, as both C. suis and C. trachomatis are known to infect the human 
conjunctival tissue and rectum, this creates an ideal in vivo opportunity for horizontal gene 
transfer to C. trachomatis (80). Co-infections with C. suis and C. trachomatis have already 
been described in patients presenting with trachoma (89), and both Helicobacter species and 
C. trachomatis may act as cofactors in the development of chlamydial proctitis (90), creating 
another milieu for genetic exchange. Marti et al. have recently showed that, while the 
frequency of such recombination in the laboratory conditions is low, the transfer of resistance 
genes may be instigated by sub-inhibitory concentrations of tetracycline antibiotics (80). 
Novel research on cassette transfer will provide us with a template for figuring the 
mechanisms and occurrence rate of resistance gene transfer among Chlamydia species (most 
notably C. trachomatis) that may be present in humans at the same anatomic sites as 
tetracycline-resistant zoonotic strains of C. suis, with substantial implications for treatment 
and public health approaches. 
 
 
7. RESISTANCE TO FLUOROQUINOLONES – POINT MUTATIONS AS A 
PREDOMINANT MECHANISM 
 
Fluoroquinolones are broad-spectrum synthetic bactericidal antimicrobial agents that 
inhibit two bacterial enzymes of the class II topoisomerase family – DNA gyrase and DNA 
topoisomerase IV (91). Several different mechanisms for resistance to fluoroquinolones have 
been elucidated, with the mutation at the target site being the most common (91). Although 
clinical response of patients infected with C. trachomatis to fluroquinolones is superb, strains 
can develop resistance in vitro when subjected to subinhibitory concentrations of the drug 
(36,46,92-94). 
 
Morissey et al. showed that initial passages of C. trachomatis strains with sub-
inhibitory concentrations of fluoroquinolones did not affect susceptibility to this group of 
drugs, but after an initial lag of at least 10 passages there was a prompt development of 
resistance to either ofloxain or ciprofloxacin (36). Furthermore, Dessus-Babus et al. showed 
that after only four passages in the presence of ofloxacin (0.5 μg/ml) and sparfloxacin (0.015 
μg/ml) spontaneous mutations were obtained and resistance ensued (93). Even after the first 
passage with subinhibitory concentrations of aforementioned antimicrobials, only a few small 
inclusions could be observed in the McCoy cell culture system (93). 
 
All the available evidence from those studies suggests that the main mechanisms of C. 
trachomatis resistance to multiple derivates of fluoroquinolones is a point mutation in the 
gyrA quinolone-resistance-determining region (QRDR), which leads to serine to isoleucine 
substitution at amino acid position 83 (according to the numbering pertinent to E. coli) in the 
corresponding protein (36,46,92,93). Although Yokoi et al. reported certain substitutions in 
ParC, those isolates remained susceptible to fluoroquinolones (94). One proposed explanation 
for ParC of C. trachomatis is that the alanine located at position 80 may be a reason for the 
lower affinity of ParC than GyrA subunit for fluoroquinolones (93), resulting in what we 
would call a privileged configuration. No literature data shows change of gyrB and parE 
QRDRs in the resistant strains when compared to the reference strains. Also, the role of other 
mechanisms of resistance to fluroquinoloes (such as drug efflux modification or drug 
permeation) may contribute to the resistance pattern (93). 
 
 
8. RESISTANCE TO RIFAMPIN – NUCLEOTIDE SUBSTITUTION MECHANISM 
 
Rifamycines and their main representative rifampin represent a group of bactericidal 
antibiotics which inhibit bacterial transcription by interacting with beta-subunit of bacterial 
DNA-dependent RNA polymerase, resulting in a potent bactericidal activity (95). Although 
they are the cornerstone of the tuberculosis treatment, they also show excellent activity 
against C. trachomatis in vitro (96). The favorable pharmacokinetics, high antimicrobial 
activity, as well as substantial cell penetration led to the belief that this class of drugs could be 
another addition to our antimicrobial armamentarium against chlamydial infections (37). 
Nevertheless, concerns about the development of resistance during treatment have 
discouraged the use of this group of drugs in the treatment of human chlamydial infections 
(97). 
 
In a small number of studies, treatment of infections caused by C. trachomatis with 
rifampin has been found to be as effective as treatment with tetracycline (37,97). MICs that 
were demonstrated in vitro against Chlamydia spp. ranged from 0.0075 to 0.03 μg/ml (98-
100), with no signs of emerging resistance in vivo. Still, several in vitro studies showed that C. 
trachomatis can easily and swiftly develop resistance after serial passages in subinhibitory 
concentrations of rifamycins – both in eggs and tissue culture (100,101). In the research 
conducted by Kutlin and his colleagues, C. trachomatis developed resistance to rifampin and 
rifalazil within six passages; higher level resistance was noted in the case of rifampin (128-
256 μg/ml), while lower level resistance was described for rifalazil (0.5-1 μg/ml) (37). 
 
Akin to a plethora of bacterial species that develop resistance to rifampin by 
nucleotide exchange in the rpoB gene responsible for coding beta-subunit of DNA-dependent 
RNA polymerase (and thus enabling bacteria to survive even high concentrations of this 
antimicrobial drug) (37,102-104), chlamydial species also show a preponderance of changes 
in the mid-portion of that gene (37,101). Therefore a substitution of only one amino acid may 
increase MIC of rifampin from 0.008 μg/ml to between 0.5 and 64 μg/ml in C. trachomatis 
belonging to D serovars, as well as between 4 and 64 μg/ml in C. trachomatis belonging to K 
serovars (46). The most common site affected with the mutation in resistant strains of C. 
trachomatis was the nucleotide at the position 471 in the gene rpoB (37,46,101). When this 
was compounded with one additional mutation, different groups of researchers have shown 
that the MIC may increase from 64 to 256 and 512 μg/ml in serovars D and K, respectively 
(101,105). 
 
On the other hand, in the research of Kutlin and his colleagues, strains resistant to 
rifalazil (as evidenced by BU-434/L2 strain) were characterized by a mutation at the 
beginning rather than at the middle of the rpoB gene (at codon 136 to be more precise) (37). 
This rare mutation is not a novel discovery, as Lisitsyn et al. found it in the rpoB gene of E. 
coli resistant to rifampin a few decades ago (106). On the other hand, in that same BU-434/L2 
strain that same group of authors observed high-level phenotypic resistance to rifampin 
without any evident genetic alterations in the rpoB gene (37), which brings into play other 
potential mechanisms of rifampin resistance described in other bacteria (such as ribosylation, 
phosphorylation and glucosylation enzymes of the activity of efflux pumps) (37). Thus far, no 
resistance has been found in C. trachomatis strains propagated in the addition of the rifamycin 
derivatives (namely 3-azinomethyl-rifamycin and rifabutin) under identical in vitro conditions 
(37). 
 
 
9. RESISTANCE MECHANISMS TO OTHER ANTIMICROBIAL DRUGS 
 
Aminoglycoside antibiotics are a family of compounds with an aminocyclitol nucleus 
(streptamine, streptidine or 2-deoxystreptamine) linked to amino sugars via glycosidic bonds 
(107). They interact with the 30S ribosomal subunit, interfering in turn with the initiation of 
genetic material translation (107). Since this family exhibits poor penetration into the 
mammalian cells, MIC values for C. trachomatis are quite high (approximately 1 mg/ml) (46); 
therefore, these drugs are not used in routine clinical conditions, albeit certain research 
endeavors were pursued using kasugamycin and spectinomycin to see whether 
aminoglycoside-resistant strains of C. trachomatis would develop (46). This was indeed 
shown for kasugamycin, where resistant C. trachomatis strains carried a two-nucleotide 
insertion in ksgA gene that encodes a protein responsible for post-transcriptional methylation 
of adenosine residues in the ribosome (108). Conversely, spectinomycin-resistant C. 
trachomatis strains have hitherto not been generated, most likely as a result of (safeguarding) 
dual rRNA and dual drug target sites (46,109). 
 
Lincomycin is a bacteriostatic agent that is widely used in clinical practice, stimulating 
dissociation of peptidyl-tRNA from ribosomes (110). It has not been used nor widely research 
in regards to C. trachomatis, although there has been one report of lincomycin-resistant C. 
trachomatis strains generated in vitro after the infected cells were grown and passaged in 
subinhibitory concentrations of antibiotic (46,110). Characteristic for these mutant strains 
were mutations in both 23S ribosomal RNA genes that corresponded to the same sites in E. 
coli with comparable resistance response (110). 
 
A combination of trimethoprim and a sulfonamide can successfully interfere with and 
block the synthesis of folic acid which is pivotal for bacterial growth (111). Sulfonamides 
competitively inhibit the incorporation of para-aminobenzoic acid into folic acid, preventing 
in turn the synthesis of folic acid, whereas trimethoprim binds to and inhibits dihyrofolate 
reductase, also decreasing folic acid synthesis by preventing the formation of tetrahydrofolic 
acid (111). One paper described stable trimethoprim-resistant strains of C. trachomatis after 
in vitro culturing in subinhibitory concentrations of the antimicrobial drug (110) – these were 
in very low frequencies (less than 5 × 10−10) as a result of mutations in the folA gene (coding 
for dihydrofolate reductase) (112). 
 
 
10. CONCLUSION 
 
Antimicrobial resistance arises as the result of the perpetual evolutionary struggle 
between hosts and pathogens, and as we aimed to demonstrate, various genetic changes 
represent the main mechanism in pathogenic bacteria (113). In C. trachomatis such events 
may involve mutations in conserved regions of 23S rRNA genes, horizontal gene transfer, 
nucleotide substitution and a myriad of other significant mechanisms. For one small, 
intracellular bacterial species, it is a rather rich repertoire of mechanisms responsible for 
developing resistance to antimicrobial agents (although its occurrence is still mostly confined 
to the in vitro setting). In order to ensure long-term and effective management of all infections 
caused by C. trachomatis we should be adequately prepared for the possibility of further 
development of clinically significant antibiotic resistance, as well as refine our approaches to 
livestock management, with an end-goal of preventing the rise of antibiotic resistance. As 
researchers have already shown, the use of antibiotic-resistant strains in research settings may 
lead to improved understanding of C. trachomatis recombination in vitro and the genetic 
underlying different phenotypic traits and growth characteristics of chlamydial strains (114). 
Consequently, this will open the doors for the use of evolutionary solutions in the 
development of new drugs and compounds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Laboratory determined C. trachomatis resistance in patients with clinical treatment 
failure 
Tested antimicrobial drug 
Number of clinical 
isolates 
Laboratory detected 
minimal inhibitory 
concentrations 
(MICs) 
Reference 
tetracycline, doxycycline, 
erythromycin 
5 ≥8 µg/ml 39 
tetracycline 1 > 64 µg/ml 40 
doxycycline, ofloxacin, 
azithromycin 
3 >4 µg/ml 41 
ciprofloxacin, ofloxacin, 
pefloxacin 
14 4-64 µg/ml 42 
doxycycline, azithromycin 5 4-8 µg/ml 43 
 
 
 
 
Figure 1. The life cycle of Chlamydia trachomatis; Photographs present C. trachomatis 
grown in McCoy cell culture and detected in different stages of infection using fluorescein-
labelled monoclonal antibodies against lipopolysaccharide antigen (Pathfinder®, Bio-Rad 
Laboratories, France). Legend: ET = elementary body; RT= reticulate body. 
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